About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Three Biomarkers To Detect Effectiveness of Schizophrenia Drugs

by Julia Samuel on November 24, 2017 at 1:40 PM
Font : A-A+

Three Biomarkers To Detect Effectiveness of Schizophrenia Drugs

 Biomarkers that can aid in the development of better treatments for schizophrenia have been identified.

In the past two decades, the pharmaceutical industry has spent over $2.5 billion to develop new schizophrenia drugs. But while many appear to be effective in animal models, most fail when tested in late-stage human clinical trials.

Advertisement


"While a great deal of money has been invested in developing schizophrenia drugs, a similar investment hasn't been made to develop biomarkers that could improve the reliability and consistency of test results," said Daniel Javitt, MD, PhD, professor of psychiatry and Director of the Division of Experimental Therapeutics at CUMC.

The National Institute of Mental Health's FAST Initiative, which was established to validate the use of biomarkers to facilitate drug development, aligns with the 21st Century Cures Act passed last year by Congress. The legislation authorized the U.S. Food and Drug Administration to approve treatments based on biomarker data alone, and created a formal Biomarker Qualification Program.
Advertisement

In this context, FAST-Psychosis researchers identified biomarkers using MRI applications to support the development of drugs that target the glutamate system. Previous studies have shown that drugs such as phencyclidine (PCP or "angel dust") and ketamine, which block glutamate receptors, cause schizophrenia-like symptoms in healthy volunteers.

The researchers evaluated three potential biomarkers for detecting the effects of ketamine on human brain function. The largest effects were observed with a biomarker measuring increases in blood flow in the frontal regions of the brain.

This response was detected consistently among individuals who were briefly exposed to ketamine, and reliably distinguished them from those who had been given a placebo. Another measure of the concentration of glutamate/glutamine was also sensitive to ketamine brain effects.

Overall, the biomarkers were successful in identifying over 90 percent of individuals who had received ketamine, and differentiating them from all of those in the placebo group.

"These results enable us to determine whether potential treatments will be effective against patients' symptoms by testing them first in healthy volunteers and defining the best doses based on objective physiological data before conducting costly clinical trials," said Jeffrey Lieberman, MD, the Lawrence C. Kolb Professor and Chairman of the Department of Psychiatry at CUMC, and Principal Investigator of this study. If the biomarkers are approved by the FDA, the developments of this study will be the first objective biomarkers registered to permit approval of new glutamate-modulating treatments for schizophrenia.

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
Cervical Cancer Awareness Month 2022
Ultra-Low-Fat Diet
Goji Berries May Protect Against Age-Related Vision Loss
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Schizophrenia Drugs Banned in India Mental Health - Neurosis vs Psychosis Schizoaffective Disorder Mind-wandering Paranoia Anosognosia Antipsychotic Medications 

Recommended Reading
Schizophrenia
Schizophrenia is a mental disorder characterized by symptoms of thought, behavior and social ......
Schizoaffective Disorder
Schizoaffective disorder is a serious mental disorder in which the individual reflects symptoms ......
Gene Linked To Schizophrenia Risk Determines Early Brain Development
ZNF804A gene affects the structure and function of the brain during early fetal development leading ...
RNA Splicing Associated With Schizophrenia Risk
DNA regions that show alterations in gene expression which lead to the development of schizophrenia ...
Anosognosia
Anosognosia is the lack of awareness or insight in a patient to understand that he/she has a disease...
Antipsychotic Medications
Antipsychotics are the class of drugs which help in treating mental disorders like schizophrenia, bi...
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...
Drugs Banned in India
Several drugs are either banned or withdrawn after introduction in the market....
Mental Health - Neurosis vs Psychosis
Mental well-being is a concern and abnormal coping of emotions can lead to neurosis or psychosis. Me...
Mind-wandering
Mind wandering is a spontaneous and unintentional shifting of attention of thoughts from a primary t...
Paranoia
Paranoia is a false belief where the individual feels unfairly targeted or persecuted by everyone el...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2022

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
open close
CONSULT A DOCTOR
I have read and I do accept terms of use - Telemedicine

Advantage Medindia: FREE subscription for 'Personalised Health & Wellness website with consultation' (Value Rs.300/-)